Posted October 11, 2016
The Symposium took place at the Grand Hyatt and TMS Health Solutions, where participants received instruction including CME-accredited, hands-on training in TMS (Transcranial Magnetic Stimulation) therapy for treatment-resistant depression.
SAN FRANCISCO, CA, October 09, 2016 — “We were very pleased to welcome psychiatric practitioners from around the country for our second Advanced TMS Symposium from September 29-October 2 in San Francisco,” said Dr. Richard Bermudes, course faculty for TMS Health Education, as well as Chief Medical Officer for TMS Health Solutions and current president of the Clinical TMS Society.
The Symposium took place at the Grand Hyatt and nearby TMS Health Solutions clinic, where participants received instruction including CME-accredited, hands-on training in TMS (Transcranial Magnetic Stimulation) therapy for treatment-resistant depression. “We were especially excited to offer seminars on the latest advances in neuromodulation and new TMS applications from leading experts like Dr. Mark George, who pioneered TMS therapy. Stanford’s Dr. Nolan Williams presented exciting research that points to a future where we might more precisely stimulate the brain to better relieve symptoms of a multitude of conditions, including Parkinson’s disease.”
“At the symposium, we saw that new studies and clinical evidence continue to prove that TMS therapy is safe and highly effective for those who do not respond to treatment and/or medication alone,” said Dr. Karl Lanocha, Director of Education for TMS Health Solutions and Course Chair for the Advanced TMS Symposium. FDA-cleared in 2008 for treating depression, TMS therapy is an outpatient non-invasive procedure that utilizes magnetic pulses to precisely stimulate areas of the brain known to cause depression and mood disorders, without the systemic side effects of anti-depressant medication. “We’re proud to educate clinicians so that as many patients with treatment-resistant depression as possible can find relief from the terrible symptoms of this disease,” said Dr. Lanocha.
“My weekend at the TMS Health Education symposium was a very positive experience,” said Jesse Bastiaens, Resident Physician at UCSF’s Department of Psychiatry. “I had the opportunity to engage in discussions with leaders in the field and gained an appreciation for the close-knit nature and accessibility of the community. It was especially valuable for me as a resident to learn about this burgeoning field and realize it is something I can be a part of. In fact, I’m now looking to start work on clinical outcomes data analysis related to TMS.”
TMS Health Education‘s next Advanced TMS Symposium will be offered in Spring 2017. Throughout the year, the group will continue to provide community education through online and in-person clinician training, as well as patient seminars on mental health and TMS.
About TMS Therapy
Cleared by the FDA in 2008, TMS is a drug-free, non-invasive therapy for patients who suffer from treatment-resistant depression. It is administered in a physician’s office in an outpatient setting. By using an MRI-strength magnetic field to stimulate the prefrontal cortex of the brain, the core symptoms of major depression can be relieved. Unlike antidepressants or Electroconvulsive Therapy (ECT), patients undergoing TMS therapy experience minimal side effects. TMS sessions are administered in a comfortable outpatient setting, and patients can resume normal activity immediately afterward.
Headquartered in San Francisco, TMS Health Education brings together the nation’s leading academics and clinical practitioners to present the most current and relevant information on the treatment of clinical depression illness through TMS therapy. TMS Health Education is led by Dr. Richard Bermudes and Dr. Karl Lanocha, two of the nation’s leading experts on TMS therapy.